Abstracts tagged "Cardiovascular disease"

Abstract Number: 1464 • 2016 ACR/ARHP Annual Meeting
Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age
Andrea Zacarias¹, Carmen Gomez Vaquero², Francisco Javier Narváez³, Joan Miquel Nolla⁴, Miguel Angel González-Gay⁵, Carlos González-Juanatey⁶ and Javier Llorca⁷, ¹Hospital Universitari de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, ⁴Rheumatology, Bellvitge University Hospital, Barcelona, Spain, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ⁶Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁷Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is associated with a greater cardiovascular mortality than the general population of the same age and gender. Cardiovascular events prediction scales,…
Abstract Number: 1494 • 2016 ACR/ARHP Annual Meeting
Myocardial Structure, Function, and Fibrosis in Patients with Rheumatoid Arthritis and Matched Control Subjects
Michelle J. Ormseth¹, William Bradham², Comfort Elumogo³, Srikanth Palanisamy⁴, Chia Liu⁵, Mark Lawson², Jonathan Soslow², Nadine Kawel⁶, David A. Bluemke⁷ and C Michael Stein², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³National Institutes of Health, Bethesada, MD, ⁴Cornell University, Ithaca, NY, ⁵National Institutes of Health, Bethsada, MD, ⁶National Institutes of Health, Bethsada, TN, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: The prevalence of heart failure is increased 2-fold in RA; this is not explained by ischemic heart disease or other risk factors for heart…
Abstract Number: 2172 • 2016 ACR/ARHP Annual Meeting
Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Helga Radner¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies have suggested that the chronic inflammatory nature of rheumatic conditions (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) as well as psoriasis (PsO) may…
Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Edmond Ramly^1,2, Daniel Panyard³, Diane Lauver⁴, Emmanuel Sampene⁵, Zhanhai Li⁵, Heather Johnson⁶, Patrick McBride⁶, Kristin Steffen Lewicki⁷ and Christie M. Bartels⁸, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions. However, we previously found that high blood…
Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon², Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Ivan Arias de la Rosa¹, Pedro Segui¹, Pilar Font-Ugalde¹, Maria Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, M. Carmen Castro-Villegas³, Rocio Gonzalez-Conejero⁴, Constantino Martinez⁴, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras² and Nuria Barbarroja¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…
Abstract Number: 1467 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease
Erin Scanlon¹, Rekha Mankad², Cynthia S. Crowson³, Iftikhar Kullo⁴, Sharon Mulvagh², Eric L. Matteson¹, Zoran Kvrgic¹ and John M. Davis III⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Measures of arterial health may be useful in assessing the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA). The…
Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 2174 • 2016 ACR/ARHP Annual Meeting
Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Milada Cvancarova Småstuen³, Stefan Agewall⁴, Jon Elling Whist⁵ and Ivana Hollan^5,6,7,8, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁴University of Oslo, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Harvard Medical School, Boston, MA, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillahammer, Norway
Background/Purpose: The cause of the increased cardiovascular risk in inflammatory rheumatic diseases (IRDs) is still unclear. Intriguingly, selenium-deficiency, which might be caused by poor diet or…
Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…
Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Serena Fasano¹, Michele Iudici², Ilenia Pantano³, Luciana Pierro³ and Gabriele Valentini⁴, ¹Internal and Experimental Medicine Naples, Italy, Rheumatology Unit, Second University of Naples, Naples, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…
Abstract Number: 1468 • 2016 ACR/ARHP Annual Meeting
Increased Mitral and Tricuspid Valve Regurgitation Among Mexican Mestizo Patients with Rheumatoid Arthritis
Dionicio A. Galarza-Delgado¹, Jose Ramon Azpiri-Lopez², Iris J. Colunga-Pedraza¹, Rosa I. Arvizu-Rivera³, Adrian Martinez-Moreno⁴, Luis E. Gonzalez-Carrillo⁴, Miguel A. Ramos-Guzman⁴, Filiberto Hervert-Cavazos⁴, Alberto Cardenas-de La Garza¹, Raymundo Vera-Pineda⁵, Mario Alberto Garza-Elizondo¹ and Mario Alberto Benavides-González⁴, ¹Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ³Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ⁴Cardiology, Hospital Universitario UANL, Monterrey, Mexico, ⁵Cardiology., Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is chronic, systemic, inflammatory, multifactorial disease that mainly affects synovial joints. RA-patients have an increased risk of cardiovascular (CV) morbidity and…
Abstract Number: 1524 • 2016 ACR/ARHP Annual Meeting
Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism
Rabia Agca^1,2, Hennie Raterman², Suat Simsek³, Alexandre E. Voskuyl² and Mike T. Nurmohamed^1,4, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, Noodwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Autoimmune thyroid disease often coexists with RA and has been associated with an elevated cardiovascular (CV) risk, especially in hypothyroid patients. However, the existing…
Abstract Number: 2289 • 2016 ACR/ARHP Annual Meeting
Obesity and Echocardiographic Changes in the Different Stages of Gout
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov¹, ¹Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose: Studies on gout and its stages as a cardiovascular (CV) risk factor are few and with contradictory results. We compared echocardiographic parameters, known as…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 860 • 2016 ACR/ARHP Annual Meeting
Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner¹, Matthew J. Koster², Ali Ugur Unal³, Hale Gulcin Yildirim⁴, Ceylan Cikikci⁴, Cynthia S. Crowson⁵, Ashima Makol⁶, Steven R. Ytterberg⁶, Eric L. Matteson⁶, Haner Direskeneli⁷ and Kenneth J. Warrington⁶, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Accelerated atherosclerosis associated with chronic inflammation is one of the major complications of systemic inflammatory diseases. Takayasu arteritis (TAK) is a rare, systemic large-vessel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.